FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Christoph Kahl et al.|The Lancet Oncology|2014Cited by 1.7k
Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cellsSebastian Müller, Shankar Balasubramanian|Organic & Biomolecular Chemistry|2012Cited by 145
Metformin reveals a mitochondrial copper addiction of mesenchymal cancer cellsSebastian Müller, Raphaël Rodriguez|PLoS ONE|2018Cited by 35
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell DeathSylvain Garciaz, Mark A. Dawson, Andrew A. Guirguis et al.|HAL (Le Centre pour la Communication Scientifique Directe)|2023Cited by 34